Literature DB >> 27919103

Primary Care-Based Models for the Treatment of Opioid Use Disorder: A Scoping Review.

P Todd Korthuis1, Dennis McCarty1, Melissa Weimer1, Christina Bougatsos1, Ian Blazina1, Bernadette Zakher1, Sara Grusing1, Beth Devine1, Roger Chou1.   

Abstract

Greater integration of medication-assisted treatment (MAT) for opioid use disorder (OUD) in U.S. primary care settings would expand access to treatment for this condition. Models for integrating MAT into primary care vary in structure. This article summarizes findings of a technical report for the Agency for Healthcare Research and Quality describing MAT models of care for OUD, based on a literature review and interviews with key informants in the field. The report describes 12 representative models of care for integrating MAT into primary care settings that could be considered for adaptation across diverse health care settings. Common components of existing care models include pharmacotherapy with buprenorphine or naltrexone, provider and community education, coordination and integration of OUD treatment with other medical and psychological needs, and psychosocial services and interventions. Models vary in how each component is implemented. Decisions about adopting MAT models of care should be individualized to address the unique milieu of each implementation setting.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27919103      PMCID: PMC5504692          DOI: 10.7326/M16-2149

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  42 in total

1.  The science and practice of medication-assisted treatments for opioid dependence.

Authors:  Anna Pecoraro; Michelle Ma; George E Woody
Journal:  Subst Use Misuse       Date:  2012 Jun-Jul       Impact factor: 2.164

2.  Integration of buprenorphine for substance-abuse treatment by HIV care providers.

Authors:  Gerald Friedland; David Vlahov
Journal:  J Acquir Immune Defic Syndr       Date:  2011-03-01       Impact factor: 3.731

3.  Drug treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine/naloxone.

Authors:  David A Fiellin; Linda Weiss; Michael Botsko; James E Egan; Frederick L Altice; Lauri B Bazerman; Amina Chaudhry; Chinazo O Cunningham; Marc N Gourevitch; Paula J Lum; Lynn E Sullivan; Richard S Schottenfeld; Patrick G O'Connor
Journal:  J Acquir Immune Defic Syndr       Date:  2011-03-01       Impact factor: 3.731

4.  Neonatal abstinence syndrome after methadone or buprenorphine exposure.

Authors:  Hendrée E Jones; Karol Kaltenbach; Sarah H Heil; Susan M Stine; Mara G Coyle; Amelia M Arria; Kevin E O'Grady; Peter Selby; Peter R Martin; Gabriele Fischer
Journal:  N Engl J Med       Date:  2010-12-09       Impact factor: 91.245

5.  A trial of integrated buprenorphine/naloxone and HIV clinical care.

Authors:  Lynn E Sullivan; Declan Barry; Brent A Moore; Marek C Chawarski; Jeanette M Tetrault; Michael V Pantalon; Patrick G O'Connor; Richard S Schottenfeld; David A Fiellin
Journal:  Clin Infect Dis       Date:  2006-12-15       Impact factor: 9.079

6.  Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome.

Authors:  Hendree E Jones; Rolley E Johnson; Donald R Jasinski; Kevin E O'Grady; Christian A Chisholm; Robin E Choo; Michael Crocetti; Robert Dudas; Cheryl Harrow; Marilyn A Huestis; Lauren M Jansson; Michael Lantz; Barry M Lester; Lorraine Milio
Journal:  Drug Alcohol Depend       Date:  2005-07       Impact factor: 4.492

7.  Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.

Authors:  Evgeny Krupitsky; Edward V Nunes; Walter Ling; Ari Illeperuma; David R Gastfriend; Bernard L Silverman
Journal:  Lancet       Date:  2011-04-30       Impact factor: 79.321

Review 8.  Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence.

Authors:  Richard P Mattick; Courtney Breen; Jo Kimber; Marina Davoli
Journal:  Cochrane Database Syst Rev       Date:  2009-07-08

9.  Oregon's Medicaid Coordinated Care Organizations.

Authors:  K John McConnell
Journal:  JAMA       Date:  2016-03-01       Impact factor: 56.272

10.  Community Outbreak of HIV Infection Linked to Injection Drug Use of Oxymorphone--Indiana, 2015.

Authors:  Caitlin Conrad; Heather M Bradley; Dita Broz; Swamy Buddha; Erika L Chapman; Romeo R Galang; Daniel Hillman; John Hon; Karen W Hoover; Monita R Patel; Andrea Perez; Philip J Peters; Pam Pontones; Jeremy C Roseberry; Michelle Sandoval; Jessica Shields; Jennifer Walthall; Dorothy Waterhouse; Paul J Weidle; Hsiu Wu; Joan M Duwve
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2015-05-01       Impact factor: 17.586

View more
  91 in total

1.  Management of Opioid Misuse and Opioid Use Disorders Among Youth.

Authors:  Camille A Robinson; J Deanna Wilson
Journal:  Pediatrics       Date:  2020-05       Impact factor: 7.124

2.  Interpretation and integration of the federal substance use privacy protection rule in integrated health systems: A qualitative analysis.

Authors:  Aimee N C Campbell; Dennis McCarty; Traci Rieckmann; Jennifer McNeely; John Rotrosen; Li-Tzy Wu; Gavin Bart
Journal:  J Subst Abuse Treat       Date:  2018-11-19

3.  Patterns of buprenorphine use and risk for re-arrest among highly vulnerable opioid-involved women released from jails in rural Appalachia.

Authors:  Hilary L Surratt; Michele Staton; Carl G Leukefeld; Carrie B Oser; J Matthew Webster
Journal:  J Addict Dis       Date:  2018-12-21

4.  Unmet mental health and substance use treatment needs among older homeless adults: Results from the HOPE HOME Study.

Authors:  Lauren M Kaplan; Lea Vella; Elise Cabral; Lina Tieu; Claudia Ponath; David Guzman; Margot B Kushel
Journal:  J Community Psychol       Date:  2019-08-19

5.  The payer's role in addressing the opioid epidemic: It's more than money.

Authors:  Todd Molfenter; Dennis McCarty; Nora Jacobson; Jee-Seon Kim; Sanford Starr; Mark Zehner
Journal:  J Subst Abuse Treat       Date:  2019-04-04

6.  The Washington State Hub and Spoke Model to increase access to medication treatment for opioid use disorders.

Authors:  Sharon Reif; Mary F Brolin; Maureen T Stewart; Thomas J Fuchs; Elizabeth Speaker; Shayna B Mazel
Journal:  J Subst Abuse Treat       Date:  2019-07-19

7.  Treating opioid dependence with extended-release naltrexone (XR-NTX) in Ukraine: Feasibility and three-month outcomes.

Authors:  Iuliia Makarenko; Iryna Pykalo; Sandra A Springer; Alyona Mazhnaya; Ruthanne Marcus; Sergii Filippovich; Sergii Dvoriak; Frederick L Altice
Journal:  J Subst Abuse Treat       Date:  2019-05-10

8.  A comparison of buprenorphine and psychosocial treatment outcomes in psychosocial and medical settings.

Authors:  Ned J Presnall; D A Patterson Silver Wolf; Derek S Brown; Sara Beeler-Stinn; Richard A Grucza
Journal:  J Subst Abuse Treat       Date:  2019-06-15

9.  Cost of pharmacotherapy for opioid use disorders following inpatient detoxification.

Authors:  Kathryn E McCollister; Jared A Leff; Xuan Yang; Joshua D Lee; Edward V Nunes; Patricia Novo; John Rotrosen; Bruce R Schackman; Sean M Murphy
Journal:  Am J Manag Care       Date:  2018-11       Impact factor: 2.229

10.  Multi-model implementation of evidence-based care in the treatment of opioid use disorder in Pennsylvania.

Authors:  Sarah Kawasaki; Erica Francis; Sara Mills; Glenn Buchberger; Ruth Hogentogler; Jennifer Kraschnewski
Journal:  J Subst Abuse Treat       Date:  2019-08-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.